EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer

NCT ID: NCT03542799

Last Updated: 2018-05-31

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-05-22
• Study Completion Date: 2021-05-23

Brief Summary

This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR -IL12 -CART) cells in metastatic patients with colorectal cancer.

Detailed Description

This is a study for the patients with colorectal cancer. Maximum tolerated dose climbing test is expected into the group of 9 cases of patients. And Phase II expected into the group of 11 subjects, selected the above safe dose, carrying out a research into the clinical effectiveness. Subjects will be collected their T cells and modify them, the modification is a genetic change, that EGFR:4-1BB:CD28:CD3 modified T cells, in order to tells the T cells to recognize their target tumor cells and potentially kill them, but not other normal cells in the subject's body. The CART cells will then be expanded in vitro and then administered to subjects. Fourth generation CART, also known as TRUCKs (T cells redirected for universal cytokine before), mainly in order to improve the effect of solid tumor treatment and design, through NFAT transcription factors inducing expression of IL - 12, overcome the solid tumor within the tumor microenvironment of CART limit the function of cellsThe purpose of this study is observe the MTD and to assess the safety and feasibility of CART cells in the patients with metastatic colorectal cancer.

Conditions

Metastatic Colorectal Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

3

anti-tumor response of EGFR IL12 CART

Group Type: EXPERIMENTAL

EGFR IL12 CART

Intervention Type: BIOLOGICAL

EGFR IL12 CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%)

Interventions

EGFR IL12 CART

EGFR IL12 CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%)

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Patients must be 18 years to 70 years;

2. Clinical diagnosis of EGFR positive for patients with metastatic colorectal cancer;

3. Patients must have a KPS of >80, expected survival > 3 months;

4. Patients must have at least one measurable lesions;

5. Recently did not use glucocorticoid;

6. Patients must have evidence of adequate hepatic and renal function as evidenced by the following laboratory parameters: WBC ≥ 3.0×109/L, Hb ≥90 g/L, PLT ≥100×109/L）; AST ≤2.5ULN，ALT ≤ 2.5ULN; Cr≤ 3ULN; TBIL≤ 3ULN，

7. Patients must have a good heart function (LVEF>50%) ;

8. Patients must be willing to practice birth control during and for three months following treatment.NOTE:female participants of reproductive potential must have a negative serum pregnancy test, and willing to practice birth control during and for three months following treatment；

9. Patients must be willing to sign an informed consent.

Exclusion Criteria

1. Patients with other cancer history;

2. Patients allergic to cetuximab;

3. Patients with severe bronchitis, bronchial asthma, or severs pneumonia;

4. Patients with uncontrolled active infections (bacteria, viruses or fungi infection) ;

5. Patients with acute and chronic GVHD (graft versus host disease)

6. Patients with severe autoimmune diseases;

7. Previously treatment with T cell inhibitors (cyclophosphamide, FK506);

8. Patients with active hepatitis B or hepatitis C infection, HIV infection, syphilis serology reaction positive;

9. Patients who are participating or participated any other clinical research in the past 1 months;

10. Pregnant and/or lactating women will be excluded; -

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The Pregene (ShenZhen) Biotechnology Company, Ltd.

INDUSTRY

Sponsor Role: collaborator

Shenzhen Second People's Hospital

OTHER

Sponsor Role: lead

Responsible Party

tiangeng

Chief physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Geng Tian 13724395569 Tiangeng666@Aliyun.Com

Shenzhen, GuangGong, China

Countries

China

Facility Contacts

geng tian, DOCTOR

Role: primary

Other Identifiers

Protocol. PGCAR/EGFR012

Identifier Type: -

Identifier Source: org_study_id